Western blot analysis of collected primary tumor lysates confirmed the reduction of the expression level of the histone methyltransferase SMYD2 (SET and MYND domain-containing protein 2) in oleocanthal-treated primary tumors, as compared to that observed in the placebo control-treated group. This evidence concerns the gene SMYD2 and neoplasm.